Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
2000 2
2002 1
2003 1
2004 4
2005 6
2006 4
2007 9
2008 4
2009 4
2010 7
2011 8
2012 9
2013 8
2014 8
2015 10
2016 5
2017 5
2018 4
2019 3
2020 4
2021 7
2022 6
2023 3
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Lambert J, et al. Among authors: pautas c. Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076173 Free PMC article. Clinical Trial.
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli A, Rousselot P, Fenaux P, Preudhomme C, Chevret S, Dombret H; Acute Leukemia French Association. Castaigne S, et al. Among authors: pautas c. Lancet. 2012 Apr 21;379(9825):1508-16. doi: 10.1016/S0140-6736(12)60485-1. Epub 2012 Apr 5. Lancet. 2012. PMID: 22482940 Clinical Trial.
Prognostic impact of CEBPA mutational subgroups in adult AML.
Georgi JA, Stasik S, Kramer M, Meggendorfer M, Röllig C, Haferlach T, Valk P, Linch D, Herold T, Duployez N, Taube F, Middeke JM, Platzbecker U, Serve H, Baldus CD, Muller-Tidow C, Haferlach C, Koch S, Berdel WE, Woermann BJ, Krug U, Braess J, Hiddemann W, Spiekermann K, Boertjes EL, Hills RK, Burnett A, Ehninger G, Metzeler K, Rothenberg-Thurley M, Dufour A, Dombret H, Pautas C, Preudhomme C, Fenwarth L, Bornhäuser M, Gale R, Thiede C. Georgi JA, et al. Among authors: pautas c. Leukemia. 2024 Feb;38(2):281-290. doi: 10.1038/s41375-024-02140-x. Epub 2024 Jan 16. Leukemia. 2024. PMID: 38228680 Free PMC article.
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carré M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guièze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socié G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Récher C, Dombret H. Hunault M, et al. Among authors: pautas c. NEJM Evid. 2025 Jul;4(7):EVIDoa2400326. doi: 10.1056/EVIDoa2400326. Epub 2025 Jun 24. NEJM Evid. 2025. PMID: 40552969 Clinical Trial.
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.
Fandrei D, Pegliasco J, Pasquier F, Ibrahim N, Kfoury M, Berthon C, Heiblig M, Lebon D, Marçais A, Meunier M, Al Jijakli A, Lemasle E, Chantepie S, Pautas C, Dumas PY, Salanoubat C, Carp D, Loyaux R, Quivoron C, Pages A, Job B, Jelin R, Jules-Clement G, Antony-Debré I, Renneville A, Cotteret S, Itzykson R, Dombret H, Duployez N, Droin N, Leary A, Marzac C, Bernard E, Micol JB. Fandrei D, et al. Among authors: pautas c. Clin Cancer Res. 2025 Jun 3;31(11):2241-2253. doi: 10.1158/1078-0432.CCR-24-3683. Clin Cancer Res. 2025. PMID: 40162927
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C. Dumas PY, et al. Among authors: pautas c. Leukemia. 2023 Jan;37(1):91-101. doi: 10.1038/s41375-022-01742-7. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376378 Free article.
How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.
Yafour N, Beckerich F, Bulabois CE, Chevallier P, Daguindau E, Dumesnil C, Guillaume T, Huynh A, Masouridi Levrat S, Menard AL, Pautas C, Poiré X, Ravinet A, Michallet M, Bazarbachi A. Yafour N, et al. Among authors: pautas c. Curr Res Transl Med. 2017 Apr-Jun;65(2):65-69. doi: 10.1016/j.retram.2017.06.001. Epub 2017 Jul 4. Curr Res Transl Med. 2017. PMID: 28687223 Review.
[ABO incompatibility and non myeloablative allogeneic stem cell transplantation].
Malfuson JV, Hicheri Y, Bonin P, Rodet M, Boccaccio C, Pautas C, Kuentz M, Cordonnier C, Noizat-Pirenne F, Maury S. Malfuson JV, et al. Among authors: pautas c. Transfus Clin Biol. 2007 Aug;14(3):327-33. doi: 10.1016/j.tracli.2007.03.002. Epub 2007 Apr 25. Transfus Clin Biol. 2007. PMID: 17462938 Review. French.
106 results